Premium
An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia
Author(s) -
Viola Assunta,
Falco Claudio,
D'Elia Rossella,
D'Amico Maria R.,
Vicari Laura,
Tambaro Francesco P.,
Correale Pasqualino,
Laudati Daniela,
Palmieri Salvatore,
Ferrara Felicetto
Publication year - 2007
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2006.00777.x
Subject(s) - medicine , leukapheresis , cd34 , myeloid leukemia , stem cell , apheresis , hematopoietic stem cell transplantation , autologous stem cell transplantation , myeloid , haematopoiesis , leukemia , transplantation , oncology , gastroenterology , immunology , surgery , platelet , biology , genetics
Several studies have reported data on factors influencing mobilization of peripheral blood stem cells (PBSC) in non‐myeloid malignancies. On the contrary, data from patients with acute myeloid leukemia (AML) are very limited, in particular, as the impact of an antecedent diagnosis of refractory anemia with excess blasts (RAEB) on mobilization of PBSCs as well as hematopoietic recovery after autologous stem cell transplantation (ASCT) is concerned. We retrospectively analyzed a cohort of 150 consecutive AML patients in first complete remission in order to make a comparison between patients with de novo AML and secondary AML (s‐AML) in terms of CD34 positive (CD34+) cells mobilization and number of leukapheresis needed to collect at least one single stem cell graft. Data concerning hematopoietic recovery after ASCT were also compared. The successful mobilization rate (>2 × 10 6 CD34+ cells/kg) was comparable between de novo AML patients (87%) and those with s‐AML (76%), P :0.21. No statistically significant difference was found in terms of either median number of CD34+ cells collected ( P :0.44) or CD34+ cells peak in peripheral blood ( P :0.28). Both groups of patients needed a median of two apheresis ( P :0.45) and no difference was found on the median number of CD34+ cells collected per single apheresis ( P :0.59). Finally, neutrophil and platelet recovery after ASCT were comparable between the two groups. An antecedent diagnosis of RAEB has no impact on mobilization and collection of PBSCs in AML as well as on hematopoietic recovery after ASCT.